Spyre Q4 2022 Earnings Report
Key Takeaways
Aeglea BioTherapeutics reported Q4 2022 financial results, including development fee revenues of $0.2 million and a net loss of $18.8 million. The company's cash, cash equivalents, marketable securities, and restricted cash totaled $57.3 million as of December 31, 2022, expected to fund operations into Q4 2023.
Jeffrey Goldberg appointed president and CEO.
Senior management team strengthened with appointments of chief medical officer and chief product officer.
Cash, cash equivalents, marketable securities, and restricted cash totaled $57.3 million as of December 31, 2022, expected to fund operations into Q4 2023.
Received Fast Track Designation from the FDA for Pegtarviliase in Homocystinuria.
Spyre
Spyre
Spyre Revenue by Segment
Forward Guidance
Aeglea expects its cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.